TY  - JOUR
AU  - Thierauf, Julia
AU  - Weissinger, Stephanie E
AU  - Veit, Johannes A
AU  - Affolter, Annette
AU  - Laureano, Natalia K
AU  - Beutner, Dirk
AU  - Heiduschka, Gregor
AU  - Kadletz, Lorenz
AU  - Meyer, Moritz
AU  - Quaas, Alexander
AU  - Plinkert, Peter
AU  - Hoffmann, Thomas K
AU  - Hess, Jochen
TI  - Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage.
JO  - PLoS one
VL  - 13
IS  - 3
SN  - 1932-6203
CY  - Lawrence, Kan.
PB  - PLoS
M1  - DKFZ-2018-00505
SP  - e0194989 -
PY  - 2018
AB  - The transcription factor SOX2 has been identified as a lineage survival oncogene in squamous cell carcinoma and copy number gain is a common event in several human malignancies including head and neck cancer. However, the regulation and function of SOX2 during carcinogenesis as well as its prognostic value appears to be highly context dependent. As an example, high SOX2 expression in lung squamous cell carcinoma (SCC) is related to a favorable prognosis, while it is associated with poor outcome in lung adenocarcinoma. More recently, higher SOX2 levels and improved survival was also reported for head and neck SCC (HNSCC), and silencing of SOX2 expression in HNSCC cell lines revealed a mesenchymal-like phenotype with prominent vimentin expression. So far, SOX2 expression and its clinical relevance for other head and neck cancers, such as adenoid cystic carcinoma (HNACC) have not been sufficiently investigated.SOX2, vimentin and E-cadherin expression was assessed by immunohistochemical staining on serial sections from formalin fixed and paraffin embedded tissue samples of a patient cohort (n = 45) with primary ACC and correlated with patient and tumor characteristics as well as survival.High SOX2 expression was found in 14 (31
LB  - PUB:(DE-HGF)16
C6  - pmid:29596469
C2  - pmc:PMC5875788
DO  - DOI:10.1371/journal.pone.0194989
UR  - https://inrepo02.dkfz.de/record/132862
ER  -